Results 81 to 90 of about 35,846 (211)
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Diabetes, Metabolic Syndrome and Obesity, 2013 Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the
Gallwitz B
doaj
BMC Geriatrics, 2017 Background Preventable drug-related hospital admissions can be associated with drugs used in diabetes and the benefits of strict diabetes control may not outweigh the risks, especially in older populations.
Gisela Schott +8 more
doaj +1 more source
DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics
The Canadian Journal of Hospital Pharmacy, 2016 -
Arden R, Barry, Ricky D, Turgeon
openaire +3 more sources
Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
International Journal of Endocrinology, 2013 Incretin-based therapies represent one of the most promising options in type 2 diabetes treatment owing to their good effectiveness with low risk of hypoglycemia and no weight gain. Other numerous potential beneficial effects of incretin-based therapies
Martin Haluzík +2 more
doaj +1 more source
Advantages of incretin-based treatment in management of type 2 diabetes [PDF]
, 2017 The risk of hypoglycemia with sulfonylureas is higher in the presence of diabetic nephropathy. Selective DPP-4 inhibitors lead to physiologic increases in the incretins GLP-1 and gastric inhibitory polypeptide and preferable for the management of ...
Abbas, Ahmad L. +3 more
core
Inappropriate Use of DPP-4 Inhibitors
, 2014 Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents for the treatment of type 2 diabetes. They have shown reduction of blood glucose, but potential impact on cardiovascular outcomes and long-term safety remain inconclusive. For that reasons DPP-4[for full text, please go to the a.m. URL]
Reichel, A +4 more
openaire +1 more source
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis
BMJ Case Reports, 2019 Sitagliptin is a dipeptidyl peptidase-4 inhibitor commonly used in the treatment of type 2 diabetes mellitus for glycaemic control. Concerns have arisen regarding adverse events caused by this drug, particularly concerning arthralgias. Here, we report on a 56-year-old man being treated with sitagliptin who developed inflammatory arthritis after taking ...
Simonette, Padron +3 more
openaire +3 more sources
Alogliptin benzoate for management of type 2 diabetes
Vascular Health and Risk Management, 2015 Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj
Сахарный диабет, 2014 The introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 diabetes mellitus (T2DM). The unique mechanism of action allows using these agents both as monotherapy and in combination with conventional anti-diabetes drugs ...
Elena Valer'evna Biryukova
doaj +1 more source
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes [PDF]
, 2017 Diabetic nephropathy (DN) is now the single commonest cause of end-stage renal disease (ESRD) worldwide and one of the main causes of death in diabetic patients.
Fernandes, Rosa +3 more
core +3 more sources